Top Stories News

Total cost base to be reduced by $3 billion by the end of 2019.

Drug trials provide mind-blowing results.

MSD's announcement to establish UK Discovery Centre in London an 'endorsement' of the government's Industry Strategy.

Controlled-release technologies will continue to be focal point, whereas techniques to improve solubility are likely to gain popularity.

Company's decision affects approximately 225 staff, specialised in tablet manufacturing, and in sachet and stick pack filling, primarily for powders and granules.

19 winners chosen from 200 entries, received from nearly 30 countries worldwide.

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee.

CDMO, Micro-Sphere partners with German machine manufacturer Harro Höfliger for the latest step in its 21 million CHF (€19 million) investment into its facility in Switzerland.

Cambrex's new HP API facility in Charles City, Iowa - one of a limited number authorized by the US DEA to import narcotic raw materials at commercial scale - to offer clients complete flexibility across scale.

The importance of ensuring a facility has the right capabilities when selecting a CMO to handle high potency ingredients.

Warning letter cites Meridian Medical Technologies' failure to thoroughly investigate multiple serious component and product failures of EpiPen products.

In connection with the $60 million settlement, the company has also resolved several private whistle-blower cases related to the government's investigation.

Mylan will reclassify EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products effective as of 1 April 2017.

Bolt-on acquisition adds value to other areas of Lonza’ business, including Health & Nutrition ingredients and excipients.

AI thought to have massive potential to reduce the cost associated with the discovery of new drugs.

Collaborations result in development of Corning Valor Glass.

Company announces investments, the sale of several products and a proposal to close a UK manufacturing site.

The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.

Discontinuation due to the vaccine supplier’s (GSK) decision to discontinue global production.

Status marks the company as the first multi-site excipient supplier to achieve global EXCiPACT accreditation across its production facilities.

New production method for solid dispersions of docetaxel and paclitaxel.

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

Settlement provides Mylan with global licenses for its trastuzumab product.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.

NTC Pharma expands its product portfolio with a new food supplement containing iron pyrophosphate microencapsulated in liposomal form, Turbofer orosoluble granules.

The molecule, which is a PPMO, will likely be ready for testing in humans in about 3 years.

Therapies targeted at this novel mechanism have the potential for disease-modification because they will address the genetic root cause of AD.

Ariad stockholders to receive $24.00 per share in cash.

Authorized generic offered at more than 50% below wholesale acquisition cost of EpiPen auto-injector.

Acquisition will make Lonza a fully integrated solutions provider in oral delivery technologies and active ingredients to the consumer healthcare and nutrition markets.

Company will also close its Hopewell, New Jersey site and will not renew its lease at the Lake Union Steam Plant site in Seattle, Washington.

Pharma giant says it complied with established competition law.

Lilly's solanezumab fails to meet primary endpoint of Phase III study.

Bococizumab deemed unlikely to provide value to patients, physicians, or shareholders.

New treatment elicits two-pronged immune response that destroys tumors in mice.

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel.

Company to continue to operate as one company with two distinct and complementary businesses to retain operating strength and financial flexibility.

Comprehensive roadmap lays out key commitments the pharmaceutical companies pledge to deliver by 2020 to reduce antimicrobial resistance.

Investment in advanced manufacturing of new respiratory and biopharmaceuticals portfolio.

This milestone marks the sixth Breakthrough Therapy Designation for Opdivo.

Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020.

Brings more than three decades of leadership and operations experience in healthcare.

Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.

New tablet attaches to the lining of the GI tract, resists being pulled away.

The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.

The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine.

Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020.

World’s largest pharma event sees record exhibitor numbers in Madrid.

As a result of the combination with Allergan and subsequent integration of the two companies, Pfizer now expects to make a decision about a potential separation of the combined company's innovative and established businesses by no later than the end of...

Transactions are consistent with the evolution of BMS’s strategic focus, including the decision to discontinue its discovery efforts in virology announced in June.

Company’s preliminary investigation indicates tha the incidents of out-of-place softgel capsules in several product batches could be related to a deliberate action by one or more individuals.

Perrigo will immediately commence its previously announced $2 billion repurchase of Perrigo shares and plans to complete $500 million of the planned repurchase by the end of 2015.

Exiting four sites to optimise capacity utilisation will affect approximately 1,200 positions.

The vaccines division of Sanofi presents at the World Vaccine Congress in Spain.

New building to feature collaboration-focused workspace.

Corporate restructuring to result in an 11% workforce reduction.

Phase III trial terminated due to insufficient efficacy.

Prize awarded for mapping, at a molecular level, how cells repair damaged DNA and safeguard the genetic information.

The FTC filed its amicus brief in a private antitrust action in which Mylan Phamraceuticals Inc. alleges that Warner Chilcott PLC/Mayne Pharma Group maintained a monopoly in the market for its antibiotic Doryx by suppressing generic competition through...

The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.

Winners from all 7 categories will be unveiled live at the event in Madrid.

Decision by Swiss Health Authority follows FDA approval of Entresto in July, and serves as an important reference approval for multiple other health authorities.

Vraylar is an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.

If approved, Vesneo will be the first nitric oxide donating prostaglandin receptor agonist available for patients with open angle glaucoma or ocular hypertension.

The plant will manufacture FlexPen prefilled devices.

Envigo has been created through the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates.

MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response, such as cell death.

Allergan's ANDA product is a generic version of Impax Laboratories' Rytary.

HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company's Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of...

Girish Malhotra believes the pharmaceutical industry should be allowed to commercialise process improvements without regulatory re-approval.

Processes improvements for original patented products need to be considered, as do improvements beyond even DMF and ANDA submission.

Frost & Sullivan webinar reveals stem cell therapy pipeline and treatments innovating regenerative medicine.

Findings from a head-to-head trial comparing Victoza (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 ...

First generic product approved from Hayward manufacturing facility following recent resolution of Warning Letter

Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, Januvia (sitagliptin), at reducing patients’ A1C levels from baseline, with similar A1C reductions achieved in both groups.

Scientific publications highlight studies using data from Thermo Scientific Orbitrap mass spectrometry and next-generation sequencing to discover how cancer attacks the protein networks controlling human cells

BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics.

The 5-year base subcontract covers studies to improve the manufacturing process and establish long-term storage of MVA-BN Filo bulk vaccine. The contract also includes options for an additional USD 24 million to implement process development activities...

Pharmaceutical professionals must develop wider commercial and business skills if they want to continue to secure the top jobs, according to NonStop Recruitment.

Dezima's lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein (CETP) inhibitor.

This is the fourth Breakthrough Therapy Designation granted for Opdivo by the FDA

Genevac has developed a suite of proprietary technological solutions to facilitate post purification sample handling, including reformatting.

The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.

The LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine ...

The expanded documentation and regulatory information facilitates drug product manufacturers' risk assessment workflows and supplier qualification. The enhancements also help drug product manufacturers meet their own internal quality guidelines as well...

Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods.